Despite efficacy gains, considerations around tolerability and convenience remain pivotal in shaping treatment choices for lung cancer patients. Continue reading J&J’s Rybrevant Takes Lead in Lung Cancer Treatment Landscape
Published February 28, 2024 Bayer’s BAY 2927088, a reversible tyrosine kinase inhibitor (TKI) developed in collaboration with the Broad Institute of MIT and Harvard, is currently undergoing a Phase I trial projected to enroll 460 patients. The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Bayer for BAY 2927088 in the treatment of non-small cell lung cancer (NSCLC). This orally administered … Continue reading Breakthrough Therapy Designation Granted to Bayer’s BAY 2927088 for Non-Small Cell Lung Cancer Treatment
The groundbreaking study, also published in The New England Journal of Medicine, heralds a new era in the management of severe food allergies. With FDA approval secured and promising results in hand, Roche’s Xolair emerges as a beacon of hope for millions grappling with the daily challenges posed by food allergies. Continue reading Roche’s Xolair Shows Promise in Reducing Severe Food Allergies, Earns FDA Approval
Published January 30, 2024 Overview: Good news emerged from Vertex Pharmaceuticals (NASDAQ: VRTX) on Tuesday, leading to a surge in the company’s stock. The positive developments center around VX-548, an investigational drug designed to address moderate to severe acute pain. Despite a slight setback in meeting a secondary endpoint, the primary goal of pain reduction was achieved, sparking optimism in the market. Clinical Trial Success: … Continue reading Vertex Pharmaceuticals Reports Positive Results for VX-548 in Phase 3 Trials
This strategic collaboration represents a fusion of expertise, innovation, and a shared commitment to enhancing eye care solutions. The partnership is expected to broaden the availability of quality hypochlorous acid products for the treatment of blepharitis, offering a unique and effective solution for individuals across the European Union. Stay tuned for further updates on this exciting venture from NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. Continue reading NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. Announce Strategic Partnership for Avenova®-Branded Products in the European Union
Novartis is addressing a temporary shortage of Pluvicto by significantly expanding its manufacturing capabilities. The Swiss pharmaceutical company has unveiled a new commercial radiotherapy facility in Indianapolis, marked as its largest and most advanced globally, receiving FDA approval for the production of commercial doses of Pluvicto. Previously dedicated to Pluvicto production for clinical trials, the 70,000-square-foot facility is designed for radioligand therapies, a focal point for Novartis. Continue reading Novartis Elevates Pluvicto Production: Expanding Capacity with Advanced Indianapolis Facility and Global Reach
In a groundbreaking decision, the Food and Drug Administration (FDA) has granted approval to Florida to import medications worth millions of dollars from Canada, marking a significant departure from decades of resistance by the pharmaceutical industry. This move is anticipated to open avenues for other states to follow suit and explore similar initiatives, with supporters hopeful for a breakthrough in the perennial battle against soaring drug prices in the United States. Continue reading Pharmaceutical Industry Opposes Move as States Seek to Slash Drug Prices through Importation
Published January 4, 2024 In a significant development, Agios Pharmaceuticals (AGIO.O) has reported positive results from its late-stage study of the drug mitapivat, bringing the company closer to obtaining approval for the first-ever oral treatment for less severe forms of thalassemia, an inherited blood disorder. The study demonstrated a statistically significant increase in hemoglobin response compared with a placebo in patients with either alpha- or … Continue reading Agios Pharma’s Mitapivat Shows Promise in Late-Stage Study for Thalassemia Treatment
Published January 3, 2023 In the ever-evolving landscape of False Claims Act (FCA) cases, recent decisions by the Eighth and Sixth Circuits have ignited a circuit split, particularly concerning the interpretation of the anti-kickback statute. The rulings in United States ex rel. Cairns v. D.S. Medical, LLC, and United States ex rel. Martin v. Hathaway, et al., established that proving “but-for” causation is crucial to … Continue reading Navigating the Evolving Terrain of False Claims Act: Circuit Splits, Causation Complexities, and Whistleblower Triumphs
Published January 2, 2024 Verona Pharma plc (Nasdaq: VRNA) is delighted to announce a significant development in collaboration with its wholly-owned subsidiary, Verona Pharma, Inc. The companies have successfully secured a debt financing facility (“debt facility”) with access of up to $400 million, facilitated by funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”)—collectively referred to as the “Lenders.” This … Continue reading Verona Pharma Secures $400 Million Debt Financing for Ensifentrine Launch: A Strategic Leap Toward Respiratory Health Innovation
Lifescience Monitor 